Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Aardvark Therapeutics Inc shares valued at $96,624 were purchased by Lee Tien-Li on Sep 15 ’25. At $9.66 per share, Lee Tien-Li acquired 10,000 shares. The insider’s holdings grew to 1,543,384 shares worth approximately $14.92 million following the completion of this transaction.
Also, VICKERS VENT GLB DEEP-TECH FND purchased 10,360 shares, netting a total of over 93,413 in proceeds.
Before that, Lee Tien-Li had added 9,000 shares to its account. In a trade valued at $71,212, the Chief Executive Officer bought Aardvark Therapeutics Inc shares for $7.91 each. Upon closing the transaction, the insider’s holdings increased to 9,000 shares, worth approximately $14.72 million.
As published in their initiating research note from BTIG Research on November 07, 2025, Aardvark Therapeutics Inc [AARD] has been a Buy and the price target has been revised to $26. Analysts at Stifel started covering the stock with ‘”a Buy”‘ outlook in a report released in late September. As of June 30, 2025, H.C. Wainwright has initiated its “Buy” rating for AARD. Earlier on March 10, 2025, RBC Capital Mkts initiated its rating. Their recommendation was “an Outperform” for AARD stock.
Analyzing AARD Stock Performance
On last trading session, Aardvark Therapeutics Inc [NASDAQ: AARD] rose 3.20% to $9.67. The stock’s lowest price that day was $9.2838, but it reached a high of $9.705 in the same session. During the last five days, there has been a drop of approximately -7.55%.
Support And Resistance Levels for Aardvark Therapeutics Inc (AARD)
According to the 24-hour chart, there is a support level at 9.40, which, if violated, would cause prices to drop to 9.13. In the upper region, resistance lies at 9.82. The next price resistance is at 9.97. RSI (Relative Strength Index) is 42.17 on the 14-day chart, showing neutral technical sentiment.
Is Aardvark Therapeutics Inc subject to short interest?
Stocks of Aardvark Therapeutics Inc saw a sharp rise in short interest on 2025-11-14 jumping by 0.54 million shares to 1.1 million. Data from Yahoo Finance shows that the short interest on 2025-10-15 was 0.56 million shares. A jump of 49.06% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 6.79 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.79.
Which companies own the most shares of Aardvark Therapeutics Inc (AARD)?
In terms of Aardvark Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 21 in the next 12 months, up nearly 124.12% from the previous closing price of $9.37. Analysts anticipate Aardvark Therapeutics Inc stock to reach 24 by 2025, with the lowest price target being 18. On March 10, 2025, Morgan Stanley assigned a price target of “an Overweight” to the stock and initiated coverage with a $29.
